JP2008546792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008546792A5 JP2008546792A5 JP2008518359A JP2008518359A JP2008546792A5 JP 2008546792 A5 JP2008546792 A5 JP 2008546792A5 JP 2008518359 A JP2008518359 A JP 2008518359A JP 2008518359 A JP2008518359 A JP 2008518359A JP 2008546792 A5 JP2008546792 A5 JP 2008546792A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- psma
- abgenix
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 80
- 150000007523 nucleic acids Chemical class 0.000 claims description 77
- 239000000611 antibody drug conjugate Substances 0.000 claims description 74
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 71
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 71
- 108020004707 nucleic acids Proteins 0.000 claims description 70
- 102000039446 nucleic acids Human genes 0.000 claims description 70
- 239000002773 nucleotide Substances 0.000 claims description 64
- 125000003729 nucleotide group Chemical group 0.000 claims description 64
- 108091026890 Coding region Proteins 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 45
- 239000000427 antigen Substances 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 43
- 230000027455 binding Effects 0.000 claims description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 25
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 13
- -1 cyclohexane-1-carbonyl Chemical group 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 10
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 7
- 229960002173 citrulline Drugs 0.000 claims description 7
- 235000013477 citrulline Nutrition 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 7
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 7
- 229960000395 phenylpropanolamine Drugs 0.000 claims description 7
- 108700026244 Open Reading Frames Proteins 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 239000003098 androgen Substances 0.000 claims description 6
- 108010044540 auristatin Proteins 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 230000006037 cell lysis Effects 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 239000003246 corticosteroid Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 239000002955 immunomodulating agent Substances 0.000 claims 6
- 229940121354 immunomodulator Drugs 0.000 claims 6
- 230000002584 immunomodulator Effects 0.000 claims 6
- 208000023958 prostate neoplasm Diseases 0.000 claims 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000000588 Interleukin-2 Human genes 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 3
- 229960004618 prednisone Drugs 0.000 claims 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 2
- 206010054094 Tumour necrosis Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000025084 cell cycle arrest Effects 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- 229960003104 ornithine Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 239000004474 valine Chemical group 0.000 claims 2
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 claims 1
- BQQGAGGSEMLWRS-UHFFFAOYSA-N (4-aminophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(N)C=C1 BQQGAGGSEMLWRS-UHFFFAOYSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100032859 Protein AMBP Human genes 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 229930182817 methionine Chemical group 0.000 claims 1
- 210000004457 myocytus nodalis Anatomy 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000004007 reversed phase HPLC Methods 0.000 claims 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 0 C*C(OCc(cc1)ccc1NC)=O Chemical compound C*C(OCc(cc1)ccc1NC)=O 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69239905P | 2005-06-20 | 2005-06-20 | |
| US79236006P | 2006-04-14 | 2006-04-14 | |
| PCT/US2006/024182 WO2007002222A2 (en) | 2005-06-20 | 2006-06-20 | Psma antibody-drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013000244A Division JP6063747B2 (ja) | 2005-06-20 | 2013-01-04 | Ｐｓｍａ抗体薬物複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008546792A JP2008546792A (ja) | 2008-12-25 |
| JP2008546792A5 true JP2008546792A5 (he) | 2009-08-06 |
Family
ID=37460276
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008518359A Withdrawn JP2008546792A (ja) | 2005-06-20 | 2006-06-20 | Ｐｓｍａ抗体薬物複合体 |
| JP2013000244A Expired - Fee Related JP6063747B2 (ja) | 2005-06-20 | 2013-01-04 | Ｐｓｍａ抗体薬物複合体 |
| JP2015095276A Pending JP2015187117A (ja) | 2005-06-20 | 2015-05-07 | Ｐｓｍａ抗体薬物複合体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013000244A Expired - Fee Related JP6063747B2 (ja) | 2005-06-20 | 2013-01-04 | Ｐｓｍａ抗体薬物複合体 |
| JP2015095276A Pending JP2015187117A (ja) | 2005-06-20 | 2015-05-07 | Ｐｓｍａ抗体薬物複合体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20070160617A1 (he) |
| EP (1) | EP1912677B1 (he) |
| JP (3) | JP2008546792A (he) |
| KR (3) | KR20080031296A (he) |
| CN (2) | CN103127523A (he) |
| AU (1) | AU2006262231B2 (he) |
| BR (1) | BRPI0612529A2 (he) |
| CA (1) | CA2612762C (he) |
| DK (1) | DK1912677T3 (he) |
| ES (1) | ES2440482T3 (he) |
| HK (1) | HK1116697A1 (he) |
| NZ (1) | NZ565075A (he) |
| PL (1) | PL1912677T3 (he) |
| PT (1) | PT1912677E (he) |
| WO (1) | WO2007002222A2 (he) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244827B2 (en) * | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
| US6943235B1 (en) * | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
| US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| EP2363404B8 (en) * | 2001-10-23 | 2016-12-07 | PSMA Development Company L.L.C. | PSMA antibodies |
| US7659241B2 (en) | 2002-07-31 | 2010-02-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| US8288557B2 (en) | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| EP1726650A1 (en) * | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| EP2481427A1 (en) | 2007-03-14 | 2012-08-01 | Endocyte, Inc. | Folate-Tubulysin conjugates |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| CN101784565B (zh) | 2007-06-25 | 2014-12-10 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| ES2579323T3 (es) | 2007-07-16 | 2016-08-09 | Genentech, Inc. | Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso |
| AU2008276128B2 (en) | 2007-07-16 | 2013-10-10 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
| US9193763B2 (en) * | 2007-08-17 | 2015-11-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| WO2009026274A1 (en) * | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| US8039597B2 (en) * | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| CL2009000062A1 (es) | 2008-01-31 | 2010-05-14 | Genentech Inc | Anticuerpo humanizado anti cd79b; con modificaciones de cisterna libre; inmunoconjugado que contiene dicho anticuerpo y una droga; polinucleotido que codifica el anticuerpo; vector, celula huesped; composicion farmaceutica y uso de dicha composicion para tratar cancer, preferentemente linfomas. |
| WO2009127046A1 (en) * | 2008-04-14 | 2009-10-22 | Proscan Rx Pharma Inc. | Prostate specific membrane antigen antibodies and antigen binding fragments |
| ES2556629T3 (es) * | 2008-05-13 | 2016-01-19 | Yale University | Moléculas pequeñas quiméricas para el reclutamiento de anticuerpos contra células cancerosas |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| PL2326350T3 (pl) * | 2008-09-08 | 2014-03-31 | Psma Dev Company L L C | Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych |
| WO2010091234A2 (en) | 2009-02-06 | 2010-08-12 | The General Hospital Corporation | Methods of treating vascular lesions |
| WO2010111018A1 (en) | 2009-03-06 | 2010-09-30 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
| TWI504410B (zh) * | 2010-02-08 | 2015-10-21 | Agensys Inc | 結合至１６１ｐ２ｆ１０ｂ蛋白之抗體藥物結合物（ａｄｃ） |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| ES2581314T3 (es) * | 2010-03-02 | 2016-09-05 | Seattle Genetics, Inc. | Métodos de cribado de anticuerpos |
| JP2014518615A (ja) | 2011-04-22 | 2014-08-07 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法 |
| MX345538B (es) * | 2011-05-27 | 2017-02-03 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
| EA201391756A1 (ru) * | 2011-05-27 | 2014-05-30 | Амбркс, Инк. | Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами |
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| US10774132B2 (en) | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| MX359257B (es) * | 2012-05-04 | 2018-09-19 | Pfizer | Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna. |
| US10800856B2 (en) * | 2012-06-07 | 2020-10-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
| AU2013274078A1 (en) * | 2012-06-14 | 2015-01-29 | Ambrx, Inc. | Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| AU2013331440A1 (en) | 2012-10-16 | 2015-04-30 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
| US9636413B2 (en) | 2012-11-15 | 2017-05-02 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
| EP2929417A4 (en) * | 2012-12-07 | 2016-07-20 | 3M Innovative Properties Co | METHOD FOR PRODUCING TRANSPARENT CONDUCTORS ON A SUBSTRATE |
| CN105188766B (zh) | 2013-03-15 | 2019-07-12 | 瑞泽恩制药公司 | 生物活性分子、其偶联物及治疗用途 |
| CN105073128A (zh) * | 2013-04-03 | 2015-11-18 | Ibc药品公司 | 用于诱导对疾病的免疫应答的组合疗法 |
| US9517276B2 (en) * | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| WO2015006736A2 (en) | 2013-07-11 | 2015-01-15 | The California Institute For Biomedical Research | Coiled coil immunoglobulin fusion proteins and compositions thereof |
| MX2016005013A (es) | 2013-10-18 | 2017-02-28 | Deutsches Krebsforsch | Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata. |
| US20150110814A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| JP6908964B2 (ja) * | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー，エルエルシー | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| WO2015073896A2 (en) | 2013-11-15 | 2015-05-21 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| MX2016007865A (es) | 2013-12-17 | 2017-01-11 | Novartis Ag | Peptidos citotoxicos y conjugados de los mismos. |
| CA2947238A1 (en) | 2014-05-22 | 2015-11-26 | Synthon Biopharmaceuticals B.V. | Site-specific conjugation of linker drugs to antibodies and resulting adcs |
| EP3154997B9 (en) | 2014-06-13 | 2021-04-14 | Novartis AG | Auristatin derivatives and conjugates thereof |
| EP3689910A3 (en) | 2014-09-23 | 2020-12-02 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
| SG11201702606TA (en) | 2014-10-03 | 2017-04-27 | Massachusetts Inst Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| EP3273998B1 (en) | 2015-03-27 | 2019-09-04 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ） |
| JP2018525001A (ja) * | 2015-08-06 | 2018-09-06 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 治療用細胞内在化コンジュゲート |
| EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3 BINDING POLYPEPTIDES |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| MA43094B1 (fr) | 2016-01-25 | 2020-10-28 | Regeneron Pharma | Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation |
| MX2018011627A (es) | 2016-03-24 | 2019-01-10 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. |
| US20170296679A1 (en) | 2016-04-18 | 2017-10-19 | Intuitive Surgical Operations, Inc. | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands |
| KR20220119529A (ko) | 2016-06-02 | 2022-08-29 | 애브비 인코포레이티드 | 글루코코르티코이드 수용체 작용제 및 이의 면역접합체 |
| CN109310781B (zh) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
| CA3047491A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ） |
| EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| MA47325A (fr) | 2017-01-20 | 2019-11-27 | Juno Therapeutics Gmbh | Conjugués de surface cellulaire et compositions cellulaires et méthodes associées |
| WO2018178277A1 (en) | 2017-03-29 | 2018-10-04 | Avicenna Oncology Gmbh | New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof |
| EP3607319A1 (en) | 2017-04-07 | 2020-02-12 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| AU2018274216A1 (en) | 2017-05-24 | 2019-12-12 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| JP7224365B2 (ja) * | 2017-06-19 | 2023-02-17 | バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． | 酸性自己安定化ジョイントを有する抗体薬物複合体 |
| WO2019106609A1 (en) | 2017-12-01 | 2019-06-06 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| AU2019240403A1 (en) * | 2018-03-23 | 2020-10-08 | Seagen Inc. | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
| KR20210042120A (ko) | 2018-08-06 | 2021-04-16 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트와 튜불린 저해제의 조합 |
| FR3085952B1 (fr) | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | Conjugue anticorps-medicament comprenant des derives de quinoline |
| US20230140397A1 (en) * | 2020-03-25 | 2023-05-04 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-psma antibody-exatecan analogue conjugate and medical use thereof |
| US20230414762A1 (en) * | 2020-11-17 | 2023-12-28 | The Johns Hopkins University | Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma |
| CA3237590A1 (en) | 2021-11-09 | 2023-05-08 | James Basilion | Psma targeted conjugate compounds and uses thereof |
| WO2024027795A1 (zh) * | 2022-08-04 | 2024-02-08 | 苏州开拓药业股份有限公司 | 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1019163A (en) * | 1963-01-23 | 1966-02-02 | Robert Dorfman | A collapsible cap or the like |
| FR2554327A1 (fr) * | 1983-11-03 | 1985-05-10 | Gamerdinger Philippe | Chapeau monopiece |
| JPS61137624U (he) * | 1985-02-15 | 1986-08-27 | ||
| JPS6270126U (he) * | 1985-10-23 | 1987-05-02 | ||
| GB8814827D0 (en) * | 1988-06-22 | 1988-07-27 | Caple I | Planar article |
| JPH0460516U (he) * | 1990-09-27 | 1992-05-25 | ||
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| JPH0712435U (ja) * | 1993-07-29 | 1995-02-28 | 規子 山内 | 組み立て帽子セット |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US5804602A (en) * | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| FR2818660B1 (fr) * | 2000-12-27 | 2005-03-11 | Agronomique Inst Nat Rech | Levures transformees par des genes augmentant leur tolerance au stress froid |
| US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| US20040161776A1 (en) * | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
| EP2363404B8 (en) * | 2001-10-23 | 2016-12-07 | PSMA Development Company L.L.C. | PSMA antibodies |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7659241B2 (en) * | 2002-07-31 | 2010-02-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| WO2004067564A2 (en) * | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| BR122018071808B8 (pt) * | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| JP2008519863A (ja) * | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | Ｎ末端にアミノ安息香酸単位を有するオーリスタチン |
| WO2007008848A2 (en) * | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| CA2614436C (en) * | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
-
2006
- 2006-06-20 DK DK06785283.0T patent/DK1912677T3/da active
- 2006-06-20 CN CN201310053174XA patent/CN103127523A/zh active Pending
- 2006-06-20 KR KR1020087001546A patent/KR20080031296A/ko not_active Application Discontinuation
- 2006-06-20 JP JP2008518359A patent/JP2008546792A/ja not_active Withdrawn
- 2006-06-20 BR BRPI0612529-8A patent/BRPI0612529A2/pt not_active Application Discontinuation
- 2006-06-20 PL PL06785283T patent/PL1912677T3/pl unknown
- 2006-06-20 WO PCT/US2006/024182 patent/WO2007002222A2/en active Application Filing
- 2006-06-20 AU AU2006262231A patent/AU2006262231B2/en not_active Ceased
- 2006-06-20 NZ NZ565075A patent/NZ565075A/en not_active IP Right Cessation
- 2006-06-20 KR KR1020147013703A patent/KR20140084242A/ko not_active Application Discontinuation
- 2006-06-20 US US11/471,457 patent/US20070160617A1/en not_active Abandoned
- 2006-06-20 ES ES06785283.0T patent/ES2440482T3/es active Active
- 2006-06-20 PT PT67852830T patent/PT1912677E/pt unknown
- 2006-06-20 EP EP06785283.0A patent/EP1912677B1/en active Active
- 2006-06-20 CA CA2612762A patent/CA2612762C/en not_active Expired - Fee Related
- 2006-06-20 KR KR1020157031397A patent/KR20150126978A/ko not_active Application Discontinuation
- 2006-06-20 CN CN2006800302414A patent/CN101287498B/zh not_active Expired - Fee Related
-
2008
- 2008-10-13 HK HK08111269.3A patent/HK1116697A1/xx not_active IP Right Cessation
-
2013
- 2013-01-04 JP JP2013000244A patent/JP6063747B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-07 JP JP2015095276A patent/JP2015187117A/ja active Pending
-
2020
- 2020-07-06 US US16/921,811 patent/US20210023094A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008546792A5 (he) | ||
| JP2013100314A5 (he) | ||
| US20210023094A1 (en) | Psma antibody-drug conjugates | |
| US9242012B2 (en) | Methods for killing PSMA-expressing, taxane-resistant cancer cells | |
| JP6333882B2 (ja) | 抗体−薬剤コンジュゲート | |
| JP2015534577A5 (he) | ||
| US20150110814A1 (en) | Combination therapies with psma ligand conjugates | |
| JP2024075668A (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP7512202B2 (ja) | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 | |
| JP2019194209A (ja) | Ｐｓｍａリガンドコンジュゲートによる併用療法 | |
| JP2018515457A (ja) | カリケアマイシン構築物および使用方法 | |
| WO2023001300A1 (zh) | 艾日布林衍生物的药物偶联物 | |
| JP2019525727A (ja) | 新規の抗ｔｎｆｒｓｆ２１抗体及び使用方法 | |
| JPWO2021090062A5 (he) | ||
| ES2837927T3 (es) | Terapias de combinación con conjugados de ligando de PSMA | |
| CA2397169A1 (en) | Targeted ligands |